Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

  • Stuart E. Lacy
    Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;
  • Sharon L. Barrans
    Haematological Malignancy Diagnostic Service, St. James’s Institute of Oncology, Leeds, United Kingdom;
  • Philip A. Beer
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom;
  • Daniel Painter
    Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;
  • Alexandra G. Smith
    Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;
  • Eve Roman
    Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;
  • Susanna L. Cooke
    Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom;
  • Camilo Ruiz
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom;
  • Paul Glover
    Haematological Malignancy Diagnostic Service, St. James’s Institute of Oncology, Leeds, United Kingdom;
  • Suzan J. L. Van Hoppe
    Haematological Malignancy Diagnostic Service, St. James’s Institute of Oncology, Leeds, United Kingdom;
  • Nichola Webster
    Haematological Malignancy Diagnostic Service, St. James’s Institute of Oncology, Leeds, United Kingdom;
  • Peter J. Campbell
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom;
  • Reuben M. Tooze
    Section of Experimental Haematology, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom;
  • Russell Patmore
    Queen’s Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, United Kingdom; and
  • Cathy Burton
    Haematological Malignancy Diagnostic Service, St. James’s Institute of Oncology, Leeds, United Kingdom;
  • Simon Crouch
    Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;
  • Daniel J. Hodson
    Wellcome–MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

Description

<jats:title>Abstract</jats:title> <jats:p>Based on the profile of genetic alterations occurring in tumor samples from selected diffuse large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies proposed partially overlapping classification systems. Using clustering techniques applied to targeted sequencing data derived from a large unselected population-based patient cohort with full clinical follow-up (n = 928), we investigated whether molecular subtypes can be robustly identified using methods potentially applicable in routine clinical practice. DNA extracted from DLBCL tumors diagnosed in patients residing in a catchment population of ∼4 million (14 centers) were sequenced with a targeted 293-gene hematological-malignancy panel. Bernoulli mixture-model clustering was applied and the resulting subtypes analyzed in relation to their clinical characteristics and outcomes. Five molecular subtypes were resolved, termed MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2, along with an unclassified group. The subtypes characterized by genetic alterations of BCL2, NOTCH2, and MYD88 recapitulated recent studies showing good, intermediate, and poor prognosis, respectively. The SOCS1/SGK1 subtype showed biological overlap with primary mediastinal B-cell lymphoma and conferred excellent prognosis. Although not identified as a distinct cluster, NOTCH1 mutation was associated with poor prognosis. The impact of TP53 mutation varied with genomic subtypes, conferring no effect in the NOTCH2 subtype and poor prognosis in the MYD88 subtype. Our findings confirm the existence of molecular subtypes of DLBCL, providing evidence that genomic tests have prognostic significance in non-selected DLBCL patients. The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification.</jats:p>

Journal

  • Blood

    Blood 135 (20), 1759-1771, 2020-05-14

    American Society of Hematology

Citations (6)*help

See more

Details 詳細情報について

Report a problem

Back to top